LH vs DBVT vs IQV vs DGX

For growth investors, Quest Diagnostics Incorporated (DGX) is the stronger pick with 11.

8% revenue growth year-over-year, versus 5. 9% for IQVIA Holdings Inc. (IQV). Quest Diagnostics Incorporated (DGX) offers the better valuation at 21. 8x trailing P/E (17. 8x forward), making it the more compelling value choice. Analysts rate Labcorp Holdings Inc. (LH) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Quest Diagnostics Incorporated (DGX) is the cheapest at 21.

8x versus Labcorp Holdings Inc. at 24. 7x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Quest Diagnostics Incorporated (DGX) delivered a total return of +47.

7%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: DGX returned +181. 3% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Quest Diagnostics Incorporated (DGX) is the lower-risk stock at 0.

07β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 1715% more volatile than DGX relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Quest Diagnostics Incorporated (DGX) is pulling ahead at 11.

8% versus 5. 9% for IQVIA Holdings Inc. (IQV). On earnings-per-share growth, the picture is similar: Labcorp Holdings Inc. grew EPS 18. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, LH leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Quest Diagnostics Incorporated (DGX) is the more profitable company, earning 9.

0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DGX leads at 14. 5% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — DGX leads at 31. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, IQVIA Holdings Inc.

(IQV) trades at 14. 1x forward P/E versus 17. 8x for Quest Diagnostics Incorporated — 3. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, DGX (1.

6% yield), LH (1. 1% yield) pay a dividend. DBVT, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Quest Diagnostics Incorporated (DGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

07), 1. 6% yield, +181. 3% 10Y return). Both have compounded well over 10 years (DGX: +181. 3%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

LH, DGX pay a dividend while DBVT, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.